Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer: Randomized Multicenter Trial

What this Trial Is About

Researchers are comparing two ways of caring for patients with primary liver cancer, specifically Hepato Cellular Carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA), who undergo treatments called transarterial chemoembolization (TACE) or radioembolization (TARE). This randomized multicenter trial aims to assess patient satisfaction, safety, and clinical outcomes over a follow-up period of 7 months. The study also includes a qualitative implementation assessment and an economic evaluation to understand how acceptable, feasible, and sustainable outpatient care is compared to conventional inpatient care. The trial has two groups: one where patients receive ambulatory care, meaning they are treated as outpatients with follow-up phone calls and nursing support for 48 to 72 hours after treatment depending on the procedure, and another where patients receive conventional inpatient care with traditional hospitalization during treatment. If complications arise in the outpatient group, a special re-hospitalization plan is in place. These care pathways are compared for comfort, satisfaction, quality of life, complications, and costs. Participants will be evaluated before treatment and monitored through various visits up to 7 months after the procedure. Assessments include patient satisfaction within 72 hours post-treatment, quality of life, general condition, technical success of treatment, and any complications. The study also records economic data and long-term budget impact. Patients' adherence and safety are monitored, and outcome measures include both quantitative and qualitative evaluations to thoroughly compare outpatient and inpatient care models in this patient population.

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)